What Does Measurable Disease Mean?

"Measurable disease" sounds like a judgment about how bad things are. It is not. It is a technical yes-or-no about whether your tumors are big enough and clear enough on scans to be tracked with a ruler.

The ruler in question is RECIST, short for Response Evaluation Criteria in Solid Tumors. Version 1.1 is a common one. The FDA's guidance on cancer drug endpoints lists revised RECIST 1.1 as an appropriate response criteria set. It also says the criteria should be defined in the trial protocol before the study starts.

The label describes how disease shows up on a scan, not how you feel.

Whether a lesion counts depends on how well it can be measured. The RECIST Committee strongly recommends CT slices of 5 mm. If slices are thicker than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness. On 10 mm slices, a lesion would need to be 20 mm.

This is one reason a repeat scan is sometimes ordered on a different protocol. It is a technical requirement, not distrust of the first scan.

Nodes are measured on their short axis, the narrower width, not the long one. Three thresholds matter:

• Under 10 mm short axis: normal
• 10 mm or more short axis: pathologic (abnormal)
• 15 mm or more short axis: measurable, and can be chosen as a target

So a node at 12 mm is abnormal but does not reach the measurable size. Only two lymph nodes can be chosen as targets per person.

Lesions that are not chosen as targets are followed as non-target disease. Which kinds of disease RECIST treats as non-measurable (for example, certain bone or fluid-related findings) is a detailed question. Ask your radiologist or oncologist how your own disease is being tracked.

The radiologist does not measure everything. RECIST 1.1 caps the tracked set at 5 target lesions in total, with no more than 2 in any single organ. No more than 2 of those may be lymph nodes. Everything else is followed as non-target disease, meaning it is watched for clear worsening but not measured.

The five chosen lesions become the record. Their diameters are added into one number, the sum of diameters. Every future scan is compared against that sum.

Response is graded against that single number.

Complete response. All lesions disappear. A lymph node under 10 mm short axis is considered benign.

Partial response. The sum drops by 30% or more from baseline.

Progressive disease. The sum rises by 20% or more compared with the nadir, which is the smallest sum recorded at any point since treatment started. There is a second requirement people miss: the increase must also be at least 5 mm in absolute terms. Any new lesion also counts as progression on its own.

Stable disease. Anything in between.

The 5 mm minimum means a small percentage change on a small tumor does not count as progression by itself.

Some trials may ask for measurable disease at entry; check each trial's rules. FDA guidance explains why response is measured this way. Objective response rate is the proportion of patients whose tumors shrank by a predefined amount for a minimum time. It is calculated as complete responses plus partial responses. Stable disease is not counted in it.

Response rate depends on tumor measurements, so a trial that uses it needs disease that can be measured.

The FDA guidance also explains why the scans are read the way they are. When response rate or progression-free survival is the primary endpoint, tumor assessments generally should be verified by central reviewers blinded to which treatment each patient received.

If you are told you do not qualify for a trial on these grounds, ask two things. Whether a different trial accepts non-measurable disease. And whether a lesion that fell just under the threshold might cross it on the next scan.

Progression-free survival is defined by the FDA as the time from randomization until objective tumor progression or death, whichever comes first. It is a trial measurement. It is not a prediction for one person.

RECIST also has known blind spots. It relies on tumor shrinkage after cytotoxic therapy. With immunotherapy, an early rise in tumor burden or new lesions can be a temporary flare before the tumor burden falls, which is why immune-related criteria were developed.

• Do I have measurable disease under RECIST, and which lesions were chosen as targets?
• What is my current sum of diameters, and what was the baseline?
• What is the nadir being used for comparison?
• Is any of my disease non-measurable, and how will that be followed?
• Was the CT done at 5 mm slices or thicker?

Imaging Tests explains how CT, MRI, and PET differ. Cancer Staging covers how stage is assigned. Pathology Reports covers the tissue side of the record.

• U.S. Food and Drug Administration — Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
• FDA guidance text — Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
• RECIST 1.1 — Update and Clarification: From the RECIST Committee (PubMed Central, NIH)
• Immune-related tumour response assessment criteria: a comprehensive review (PubMed Central, NIH)